ICD-11 code 2A83 refers to plasma cell neoplasms, which are types of cancer that originate from plasma cells in the bone marrow. Plasma cells are a type of white blood cell that produce antibodies to help the body fight off infections.
Plasma cell neoplasms can manifest as different types of cancer, such as multiple myeloma or solitary plasmacytoma. These cancers can lead to symptoms such as bone pain, anemia, and kidney problems, as abnormal plasma cells multiply uncontrollably.
Treatment for plasma cell neoplasms typically involves a combination of chemotherapy, radiation therapy, and targeted therapies to target the cancerous cells and help manage symptoms. Patients with plasma cell neoplasms may also undergo stem cell transplantation to help replace damaged bone marrow cells.
Table of Contents:
- #️⃣ Coding Considerations
- 🔎 Symptoms
- 🩺 Diagnosis
- 💊 Treatment & Recovery
- 🌎 Prevalence & Risk
- 😷 Prevention
- 🦠 Similar Diseases
#️⃣ Coding Considerations
The equivalent SNOMED CT code for the ICD-11 code 2A83, which refers to Plasma cell neoplasms, is 128140001. This SNOMED CT code specifically denotes “Plasma cell neoplasm” and provides a more detailed and precise classification for this medical condition. SNOMED CT is a comprehensive and multilingual clinical terminology that facilitates the exchange of electronic health records among healthcare providers globally. By using SNOMED CT codes, healthcare professionals can accurately document and communicate patient diagnoses, treatments, and outcomes, leading to improved patient care and clinical research. Therefore, the coding system plays a vital role in the interoperability and standardization of healthcare information, ensuring consistency and accuracy across different healthcare settings.
In the United States, ICD-11 is not yet in use. The U.S. is currently using ICD-10-CM (Clinical Modification), which has been adapted from the WHO’s ICD-10 to better suit the American healthcare system’s requirements for billing and clinical purposes. The Centers for Medicare and Medicaid Services (CMS) have not yet set a specific date for the transition to ICD-11.
The situation in Europe varies by country. Some European nations are considering the adoption of ICD-11 or are in various stages of planning and pilot studies. However, as with the U.S., full implementation may take several years due to similar requirements for system updates and training.
🔎 Symptoms
Symptoms of 2A83, also known as plasma cell neoplasms, may vary depending on the specific type of condition present. Common symptoms include bone pain, particularly in the back or ribs, due to bone destruction caused by abnormal plasma cells. Patients may also experience weakness, fatigue, and anemia, as these conditions can disrupt the normal production of blood cells in the bone marrow.
In some cases, patients with plasma cell neoplasms may exhibit symptoms related to hypercalcemia, or high levels of calcium in the blood. This can lead to various symptoms such as excessive thirst, frequent urination, constipation, abdominal pain, and confusion. Additionally, patients may develop kidney dysfunction as a result of excess calcium deposition in the kidneys, leading to further complications.
Other symptoms of 2A83 may include recurrent infections, due to the suppression of normal immune function by abnormal plasma cells. Patients may experience frequent bacterial infections, such as pneumonia, urinary tract infections, and skin infections. In cases where the abnormal plasma cells infiltrate other organs, symptoms may vary depending on the affected organ, leading to a range of symptoms such as shortness of breath, abdominal pain, or neurological deficits.
🩺 Diagnosis
Diagnosis of 2A83, commonly known as Plasma cell neoplasms, typically involves a combination of physical examination, laboratory tests, imaging studies, and bone marrow biopsy. The initial step in diagnosing these conditions often begins with a thorough medical history and physical examination to evaluate symptoms such as bone pain, anemia, or hypercalcemia.
Laboratory testing plays a crucial role in the diagnosis of Plasma cell neoplasms. Blood tests such as complete blood count (CBC), serum protein electrophoresis (SPEP), and serum immunofixation electrophoresis can help identify abnormal levels of certain proteins or antibodies in the blood that are indicative of a plasma cell disorder.
Imaging studies, such as X-rays, CT scans, MRI scans, or PET scans, may be used to assess bone damage and detect any potential lesions or tumors associated with Plasma cell neoplasms. These imaging techniques can help identify abnormalities in the skeletal system, which are common manifestations of these conditions.
A definitive diagnosis of Plasma cell neoplasms often requires a bone marrow biopsy. This procedure involves extracting a small sample of bone marrow from the hip bone or sternum and examining it under a microscope for abnormal plasma cells. The presence of clonal plasma cells in the bone marrow is a key diagnostic criterion for diseases such as multiple myeloma and solitary plasmacytoma.
💊 Treatment & Recovery
Treatment for 2A83, or plasma cell neoplasms, varies depending on the specific subtype of the disease. For patients with symptomatic multiple myeloma, a combination of chemotherapy, targeted therapy, and immunotherapy may be used. Stem cell transplantation may also be considered for eligible patients to help restore normal bone marrow function and improve outcomes.
In the case of solitary plasmacytoma, localized radiation therapy is often the main form of treatment. This approach aims to target and eliminate the abnormal plasma cells in a specific area of the body. Surgery may also be employed in certain situations to remove the tumor and surrounding tissue.
For patients with smoldering multiple myeloma, close monitoring without immediate treatment may be recommended in some cases. This approach, known as watchful waiting, involves regular check-ups to assess disease progression and determine the appropriate time to initiate therapy. Clinical trials exploring novel treatment strategies are also an option for patients with plasma cell neoplasms to potentially improve outcomes and quality of life.
Recovery from plasma cell neoplasms can be a complex process that may involve ongoing treatment and management to prevent disease progression and recurrence. Following initial therapy, patients will typically undergo regular follow-up appointments to monitor their response to treatment and detect any signs of disease relapse. Supportive care, such as medication to manage symptoms and support bone health, is often an integral part of the recovery process for individuals with plasma cell neoplasms. Engaging with healthcare providers, support groups, and other resources can also help patients navigate the physical and emotional challenges associated with a diagnosis of 2A83.
🌎 Prevalence & Risk
In the United States, plasma cell neoplasms are relatively rare, accounting for approximately 2% of all malignancies of the blood and bone marrow. Multiple myeloma is the most common type of plasma cell neoplasm in the US, with an estimated prevalence of around 6.5 cases per 100,000 people. The incidence of plasma cell neoplasms is slightly higher in African Americans compared to Caucasians.
In Europe, the prevalence of plasma cell neoplasms varies by country, with higher rates reported in Eastern European countries such as Poland and Hungary. Multiple myeloma is the most common type of plasma cell neoplasm in Europe, affecting an estimated 5-6 people per 100,000 individuals. The incidence of multiple myeloma is higher in Northern European countries compared to Southern European countries.
In Asia, the prevalence of plasma cell neoplasms is lower compared to Western countries, with Japan and South Korea reporting higher rates compared to other Asian countries. Multiple myeloma is the most common type of plasma cell neoplasm in Asia, with an estimated prevalence of around 4-5 cases per 100,000 people. The incidence of plasma cell neoplasms is generally lower in Southeast Asian countries compared to East Asian countries.
In Australia and New Zealand, the prevalence of plasma cell neoplasms is similar to that of Western countries such as the United States and Europe. Multiple myeloma is the most common type of plasma cell neoplasm in Australia and New Zealand, with an estimated prevalence of around 6 cases per 100,000 individuals. The incidence of plasma cell neoplasms is slightly higher in Australia compared to New Zealand.
😷 Prevention
To prevent the development of multiple myeloma, one type of plasma cell neoplasm, individuals should avoid known risk factors such as exposure to radiation and certain chemicals. Additionally, maintaining a healthy lifestyle through regular exercise and a balanced diet may help reduce the risk of developing this condition. Regular medical check-ups and screenings can also aid in the early detection of any abnormalities that may lead to the development of multiple myeloma.
For Waldenström macroglobulinemia, another type of plasma cell neoplasm, avoidance of known risk factors such as certain viral infections and family history of the disease may help prevent its development. As with multiple myeloma, maintaining a healthy lifestyle and undergoing regular medical check-ups may aid in the early detection of any abnormalities that may lead to the development of Waldenström macroglobulinemia.
Preventive measures for primary amyloidosis, a type of plasma cell neoplasm characterized by the abnormal production of amyloid proteins, include avoidance of known risk factors such as chronic inflammation and certain genetic mutations. Individuals can also reduce their risk by maintaining a healthy diet low in saturated fats and high in fruits and vegetables. Regular medical check-ups can help detect any early signs of primary amyloidosis and initiate prompt treatment to prevent its progression.
🦠 Similar Diseases
One disease similar to Plasma cell neoplasms (2A83) is Multiple Myeloma (C90.00). Multiple Myeloma is a type of cancer that begins in plasma cells, a type of white blood cell. Like Plasma cell neoplasms, Multiple Myeloma can cause bone pain, weakness, and anemia due to the overgrowth of abnormal plasma cells in the bone marrow.
Another disease related to Plasma cell neoplasms is Monoclonal Gammopathy of Undetermined Significance (MGUS) (D47.3). MGUS is a condition in which abnormal plasma cells produce an excess of a certain type of protein, or immunoglobulin, in the blood. While MGUS may not cause any symptoms or health problems, it can sometimes progress to more serious conditions such as Multiple Myeloma or other plasma cell disorders.
Waldenström Macroglobulinemia (C88.0) is another disease that shares similarities with Plasma cell neoplasms. This rare type of non-Hodgkin lymphoma involves the overproduction of abnormal plasma cells that create an excess of a specific type of protein, or monoclonal immunoglobulin, in the blood. Like other plasma cell disorders, Waldenström Macroglobulinemia can cause symptoms such as weakness, fatigue, and anemia due to the impact of abnormal plasma cells on normal blood cell production.